Repligen Corporation ($RGEN) Stock Forecast: Up 6.0% Today

What is Repligen Corporation?

Repligen Corp (RGEN) specializes in bioprocessing technologies for the life sciences and biopharmaceutical industries, experiencing a notable 4.0% surge in its stock today.

Why is Repligen Corporation going up?

RGEN stock is up 6.0% on Jun 9, 2026 13:55

• The stock's upward momentum is linked to it being perceived as undervalued, supported by a strong GF Score of 79/100, signaling solid growth and financial health.
• Despite a recent decline post-earnings, Repligen's Q1 2026 performance outpaced expectations, showcasing robust revenue growth and an emphasis on expanding margins in its bioprocessing segment.
• The company's shift towards more lucrative bioprocessing sectors and global markets, coupled with initiatives like establishing a new Training & Innovation Center, have likely bolstered investor trust in its future prospects.
• While certain concerns like insider selling and customer concentration risks linger, Repligen's optimistic financial outlook and growth direction appear to be the driving forces behind today's bullish market movement.

RGEN Price Chart

RGEN Technical Analysis

RGEN News

Repligen Corp (RGEN) Shares Surge 4.0% -- What GF Score of 79 Te

Repligen Corp (RGEN) shares surged 4.0% to $126.55 on June 4, 2026. The stock is considered 27.7% undervalued according to GuruFocus' GF Value™ estimate of $174.94, despite its current P/E (TTM) of 140.6x being significantly above its 5-year median. The company holds a GF Score™ of 79/100, indicating strong growth and financial strength, though recent insider selling of $0.5 million suggests caution for investors.

https://www.gurufocus.com/news/8902203/repligen-corp-rgen-shares-surge-40-what-gf-score-of-79-tells-investors

Repligen (RGEN) Down 3.2% Since Last Earnings Report: Can It Rebound?

Repligen (RGEN) shares have dropped 3.2% since its last earnings report, underperforming the S&P 500. Despite this, the company's Q1 2026 adjusted earnings and revenues surpassed estimates, with strong year-over-year growth across its business franchises. While Repligen lowered its full-year 2026 revenue guidance, it raised its EPS outlook, leading to varied analyst sentiment and a Zacks Rank #3 (Hold).

https://finance.yahoo.com/sectors/healthcare/articles/repligen-rgen-down-3-2-153026362.html

Repligen (RGEN) Ups Margin Focus After Q1 2026 Beat – Is Its Bioprocessing Pivot Deepening?

Repligen (RGEN) reported a strong Q1 2026 with 15% revenue growth, including 11% organic growth, indicating a renewed focus on margin expansion and portfolio quality after a challenging previous year. The company's robust balance sheet and cash generation offer flexibility for M&A and expansion, particularly into higher-value bioprocessing areas and global markets. This strategic pivot, including the opening of a new Training & Innovation Center, reinforces its long-term investment narrative despite ongoing risks related to customer concentration and volatile market segments.

https://www.sahmcapital.com/news/content/repligen-rgen-ups-margin-focus-after-q1-2026-beat-is-its-bioprocessing-pivot-deepening-2026-06-02

Total current liabilities of Repligen Corporation – SWB:RGN

This article provides a financial snippet for Repligen Corporation (SWB:RGN), specifically focusing on its total current liabilities. It shows the period, value, and percentage change of these liabilities. The content appears to be a stub from a financial data platform like TradingView, lacking detailed analysis or a full report.

https://www.tradingview.com/symbols/SWB-RGN/financials-balance-sheet/total-current-liabilities/

Trending Today

Align Technology Inc. ($ALGN) Stock Forecast: Up 5.2% Today

Grab Holdings Limited ($GRAB) Stock Forecast: Up 7.1% Today

Electronic Arts Inc. ($EA) Stock Forecast: Down 0.4% Today

ARM Holdings plc ($ARM) Stock Forecast: Up 5.0% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Up 5.1% Today

Reddit Inc ($RDDT) Stock Forecast: Up 5.0% Today

Analog Devices Inc. ($ADI) Stock Forecast: Up 5.6% Today

Stitch Fix Inc. ($SFIX) Stock Forecast: Up 5.2% Today

Corsair Gaming Inc. ($CRSR) Stock Forecast: Up 5.6% Today

Dollar Tree Inc. ($DLTR) Stock Forecast: Up 5.3% Today

Repligen Corporation Price History

21.04.2026 - RGEN Stock was up 5.0%

• Repligen's strong bullish movement can be attributed to the positive investor sentiment surrounding the company's recent focus on ESG progress and sustainability initiatives, as highlighted in its 2025 Corporate Sustainability Report.
• The company's commitment to maintaining 100% renewable electricity in its manufacturing operations and reducing global water withdrawals by 14% has likely resonated well with investors, positioning Repligen as a leader in sustainable practices within the bioprocessing tools industry.
• The stock's 4.2% increase and undervaluation according to GuruFocus's GF Value™ may have attracted value investors looking for growth opportunities, despite concerns raised about the P/E ratio and insider selling. This mix of positive sustainability news and potential value investment opportunities could have been key drivers behind today's bullish market movement for Repligen Corp.

09.05.2026 - RGEN Stock was up 6.0%

• The stock's upward momentum is linked to it being perceived as undervalued, supported by a strong GF Score of 79/100, signaling solid growth and financial health.
• Despite a recent decline post-earnings, Repligen's Q1 2026 performance outpaced expectations, showcasing robust revenue growth and an emphasis on expanding margins in its bioprocessing segment.
• The company's shift towards more lucrative bioprocessing sectors and global markets, coupled with initiatives like establishing a new Training & Innovation Center, have likely bolstered investor trust in its future prospects.
• While certain concerns like insider selling and customer concentration risks linger, Repligen's optimistic financial outlook and growth direction appear to be the driving forces behind today's bullish market movement.

04.05.2026 - RGEN Stock was up 5.0%

• Repligen's stock price rose significantly today by 8.45% to reach USD 126.56, surpassing the S&P 500's performance.
• This uptrend is linked to Wolfe Research's initiation of coverage on Repligen with an outperform rating and a target price of $145.00, reflecting optimism about the company's prospects.
• Moreover, the overall surge in the medical instruments and supplies industry, lifting Repligen's stock by 6.2%, indicates a sector-wide positive movement affecting multiple firms simultaneously.
• Despite challenges, Repligen's recent strong financial results in Q1 2026, coupled with analyst endorsements, are likely factors contributing to the bullish market sentiment.

04.05.2026 - RGEN Stock was up 5.2%

• Repligen's strong Q1 2026 performance, with revenue growth and margin focus, has impressed analysts and investors, leading to a bullish movement in the stock.
• Analysts are optimistic about Repligen's future prospects, with coverage initiating an outperform rating and a price target of $145.00, based on the company achieving growth targets and margin improvements.
• Despite some concerns about overvaluation, the positive momentum from recent financial results and analyst coverage has driven investor confidence in Repligen's long-term investment narrative.
• The company's strategic pivot towards higher-value bioprocessing areas and global markets, as well as its strong balance sheet and cash generation, have positioned it well for future growth and expansion, contributing to the bullish market movement.

24.03.2026 - RGEN Stock was up 5.9%

• Repligen Corporation's (RGEN) stock witnessed a positive movement despite a recent 52-week low.
• The CEO's sale of company shares under a 10b5-1 plan initially sparked concerns, but the market response appears favorable, potentially interpreted as a strategic decision.
• Favorable ratings and increased price targets from analysts, in addition to the anticipation of the upcoming financial results announcement, likely contributed to the optimistic sentiment surrounding RGEN.
• The market seems hopeful about the company's growth prospects, particularly following strong Q4 2025 earnings and the establishment of a new training center in the Netherlands, signaling global expansion.

23.03.2026 - RGEN Stock was down 12.4%

• The CEO of Repligen Corp, Olivier Loeillot, sold 3,832 shares of the company, reducing his holding to 54,246 shares. This significant insider sell might have contributed to the bearish movement as it could signal lack of confidence in the company's future performance.
• Despite the CEO's sell-off, analysts have maintained positive ratings and raised price targets for Repligen, indicating underlying strength in the company's fundamentals.
• The upcoming earnings release on May 5, 2026, could also be a factor in the bearish movement as investors might be cautious ahead of the financial results, especially considering the recent insider selling activity.
• Overall, the combination of insider selling, upcoming earnings report, and market sentiment may have led to the bearish movement in Repligen Corp's stock today.

29.03.2026 - RGEN Stock was down 5.2%

• The company is expected to report a decline in earnings for the quarter, with analysts projecting a decrease in earnings per share despite higher revenues. This negative outlook likely contributed to the bearish movement in the stock.
• An insider share sale by CEO Olivier Loeillot, along with significant sales by multiple executives over the past six months, has raised concerns among investors and added to the negative sentiment surrounding the stock.
• Despite a recent gain in share price, Repligen (RGEN) has seen a significant drop over the past year, reaching a 52-week low. The company's undervaluation, coupled with insider selling and earnings uncertainties, may have intensified the selling pressure on the stock.

28.04.2026 - RGEN Stock was up 5.1%

• Today's bullish movement in RGEN's stock can be attributed to several factors:
• The release of Repligen's 2025 Corporate Sustainability Report highlighting its commitment to ESG principles and innovation likely resonated well with investors, signaling a strong long-term growth trajectory.
• The upcoming presentation at the William Blair 46th Annual Growth Stock Conference by the company's CEO further fueled optimism among analysts and investors, leading to increased buying activity.
• The combination of positive developments, including operational expansions and earnings updates, has created a favorable sentiment around Repligen, driving the stock price higher.
• The focus on sustainability, coupled with participation in key industry events, positions Repligen as a leading player in the bioprocessing market, attracting investor attention and contributing to today's bullish market movement.

13.04.2026 - RGEN Stock was down 5.5%

• The bearish movement in RGEN's stock today could be attributed to profit-taking by investors after a recent surge in the stock price.
• The news of the Chief Product Officer having shares withheld for tax obligations and a director exercising stock options might have raised concerns about insider transactions, leading to a negative sentiment in the market.
• Despite the positive financial outlook provided by Repligen, investors may be cautious due to uncertainties in the broader market or industry trends, contributing to the downward pressure on the stock.
• Participation in the upcoming Bank of America Securities Global Healthcare Conference could potentially provide a platform for Repligen to showcase its growth prospects and strategic initiatives, which might help in regaining investor confidence and stabilizing the stock price in the future.

05.04.2026 - RGEN Stock was up 5.6%

• Repligen Corporation reported impressive earnings results for the first quarter of 2026, with a significant revenue increase to $194.3 million and adjusted EPS of $0.48 per share, surpassing analyst estimates.
• The company's decision to divest its Polymem filtration business, launch a Transformation Office for margin expansion, and enter a new OEM partnership in China has likely boosted investor confidence in its growth potential.
• The increased stake in RGEN by institutional investors like Artemis Investment Management LLP and Conestoga Capital Advisors LLC further indicates positive sentiment and long-term belief in the company's performance and future prospects.
• Overall, the strong financial performance, strategic business decisions, and increased institutional investments have contributed to the bullish movement in Repligen's stock today.

05.04.2026 - RGEN Stock was up 5.2%

• Today's bullish movement in Repligen's stock is driven by the positive sentiment surrounding the company, supported by institutional investors increasing their holdings and the strong quarterly earnings report. The market appears to be responding positively to the company's performance and growth potential, resulting in an increase in the stock price.

14.04.2026 - RGEN Stock was down 5.6%

• Repligen's stock price fell by 5.4% to $107.41, aligning with a larger sector-wide sell-off impacting bioprocessing equipment suppliers, reflecting a trend that goes beyond company-specific factors.
• The concurrent declines seen among industry peers suggest a collective reassessment of positions within the sector, possibly driven by broader market sentiment or macroeconomic considerations.
• Despite internal transactions involving company insiders, like the Chief Product Officer's share withholding for tax purposes and a director's stock option exercise, these activities are unlikely to have directly caused the overall market decline in Repligen's stock.